Clinical Trials Logo

Neuromyelitis Optica clinical trials

View clinical trials related to Neuromyelitis Optica.

Filter by:

NCT ID: NCT06413654 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorders

A Phase II/III Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Start date: June 20, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.

NCT ID: NCT06398158 Not yet recruiting - Clinical trials for Neuromyelitis Optica

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

AMAZE
Start date: June 1, 2024
Phase:
Study type: Observational

This is an observational study to: - evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period prior to exposure), - enhance knowledge regarding conventional MRI outcomes in people with NMOSD treated with ravulizumab, - identify factors suggestive of subclinical disease progression through conventional MRI sequences, - determine if treatment with ravulizumab, impacts longitudinal 3D conformational MRI measures at the dorsal medulla and other regions of the CNS, and - identify biomarkers (e.g., serum neurofilament light chain (sNfL), conventional and novel MRI markers, etc.) related to disease activity.

NCT ID: NCT06374264 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorder

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

aNiMatO
Start date: June 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.

NCT ID: NCT06312644 Not yet recruiting - Pregnancy Clinical Trials

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Start date: March 29, 2024
Phase:
Study type: Observational [Patient Registry]

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

NCT ID: NCT06280755 Not yet recruiting - Multiple Sclerosis Clinical Trials

Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.

RECLAIM
Start date: March 2024
Phase:
Study type: Observational

The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to develop the tools to monitor this progression.

NCT ID: NCT06249438 Recruiting - Clinical trials for Systemic Lupus Erythematosus (SLE)

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

CAR-AID
Start date: March 20, 2024
Phase: Phase 1
Study type: Interventional

This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

NCT ID: NCT06212245 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorders

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Start date: February 25, 2024
Phase: Phase 4
Study type: Interventional

To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.

NCT ID: NCT06180278 Recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorder

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

N-MOmentum LT
Start date: April 2, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins and B-cell counts in participants with NMOSD who discontinue treatment. The objectives include: 1. To establish the nadir in circulating immunoglobulins (Ig) during chronic treatment with inebilizumab and ascertain the time needed to ensure restoration of pre-treatment baseline serum levels of IgG and IgM after discontinuation of treatment 2. To characterize B-cell counts throughout treatment with inebilizumab and after discontinuation until repletion of Immunoglobulin (Ig levels) 3. To assess long-term safety of inebilizumab 4. To assess other long-term effects of inebilizumab

NCT ID: NCT06118398 Not yet recruiting - Clinical trials for Neuromyelitis Optica

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

Start date: November 5, 2023
Phase:
Study type: Observational

This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.

NCT ID: NCT06068829 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorders

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

Start date: October 20, 2023
Phase:
Study type: Observational

To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.